酒精消费对渐进性超核麻的影响:一项横截面研究
Min Tian1, Bohan Zhang1, Heyin Liu1
1Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
CNS neuroscience & therapeutics
|December 23, 2024
概括
过度饮酒与进展性超核麻 (PSP) 患者的更严重的临床症状有关,特别是影响运动功能和认知. 这表明酒精可能会影响PSP.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 临床医学 临床医学
背景情况:
- 渐进性超核性麻 (PSP) 是一种罕见的神经退行性疾病.
- 了解影响PSP临床表现的因素对于患者管理至关重要.
研究的目的:
- 调查诊断为进展性超核麻 (PSP) 的患者的酒精消费模式和临床症状严重程度之间的关联.
主要方法:
- 一项涉及128名可能和可能的PSP患者的横截面研究.
- 数据收集包括饮酒习惯,人口统计和使用标准化秤的临床评估.
- 采用多变量线性回归分析来检查关系,控制混变量.
主要成果:
- 在PSP患者中,酒精消费与更严重的运动和认知症状有关,特别是男性.
- 与不饮酒者相比,重饮者在PSPRS和UPDRS上得分明显较差,在MoCA和MMSE上得分较低.
- 在视觉空间能力,执行功能,记忆和语言方面注意到认知障碍.
结论:
- 过度饮酒与PSP症状严重程度的增加相关,特别是影响认知领域.
- 饮酒可能会调节渐进性的临床进展和表现.
相关概念视频
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
CNS Depressants: Alcohol and Nicotine
171
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
171
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162


